Godina, Christopher
Belting, Mattias
Vallon-Christersson, Johan
Isaksson, Karolin
Bosch, Ana
Jernström, Helena
Funding for this research was provided by:
Medicinska Fakulteten, Lunds Universitet
Region Skåne (Young researcher award, Young researcher award, ALF 40620)
Skånes universitetssjukhus
Cancerfonden (CAN 20 0763 and CAN 23 2952)
Fru Berta Kamprads Stiftelse
Lund University
Article History
Received: 14 December 2023
Accepted: 18 March 2024
First Online: 20 March 2024
Competing interests
: Ana Bosch has received institutional honoraria from Pfizer, Roche and Lilly for consultation and lectures. She has participated in Advisory Board meetings for Pfizer and Novartis. Co-founder and chair of the board for SACRA therapeutics. Karolin Isaksson has received speaker honorarium from Pierre Fabre. The other authors declare no conflict of interest.